Last updated: February 16, 2026
What is NDC 70000-0132?
NDC 70000-0132 is a drug marketed under the label Zepzelca (Liposomal Irinotecan), primarily used for the treatment of metastatic small cell lung cancer (SCLC) post first-line therapy approval in the United States. The drug is developed by Takeda Pharmaceuticals.
Market Landscape Overview
Market Size & Patient Population
- Target Population: Estimated U.S. small cell lung cancer (SCLC) patients who have relapsed after initial therapy.
- Incidence & Prevalence: Approximately 13,500 new SCLC cases diagnosed annually in the U.S. (CDC, 2022).
- Post-First Line Patients: About 70-80% of SCLC patients relapse, making them eligible for second-line treatments like Zepzelca.
- Market Share Potential: Based on clinical adoption rates, approximately 10,000-12,000 patients annually could receive Zepzelca in the U.S.
Competitive Landscape
- Main competitors: Topotecan (generic), Lurbinectedin (recently FDA approved for relapsed SCLC), Cemiplimab (immune therapy, combination remains investigational).
- Market Challenges: Competition from affordable generic options and rising investigational therapies; Zepzelca benefits from FDA approval, but adoption depends on pricing, insurance reimbursement, and clinical guidelines.
Regulatory & Reimbursement Context
- FDA Approval: August 2020 for adult patients with SCLC who have received prior platinum-based chemotherapy and provided disease progression on or after platinum-based therapy.
- Pricing & Reimbursement: Projected initial wholesale price in the U.S. ranges between $6,000 to $8,000 per cycle; actual patient out-of-pocket varies with insurance coverage and assistance programs.
Price Projection Analysis
Pricing Assumptions
| Parameter |
Specification |
| Initial Wholesale Price |
$6,500 per cycle |
| Number of Cycles Needed |
Typically 4-6 cycles per patient |
| Total Treatment Cost |
$26,000 - $39,000 per patient |
| Market Penetration |
20%-30% of relapsed SCLC patients |
Projected Revenue
-
Year 1: Focused on ramp-up with 5% market penetration, approximately 500 patients.
-
Annual Revenue (Year 1):
( 500 \text{ patients} \times 4 \text{ cycles} \times \$6,500 = \$13 million )
-
Year 3 & Beyond:
With increased adoption, assuming 20% market penetration and increased cycles per patient, revenue could rise to $50-100 million annually.
Pricing Trends & Sensitivity
- Price Decreases: Emerging competition from generics could lower prices by 10-15% within 3-5 years.
- Market Expansion: If Zepzelca gains approval for earlier lines of therapy or other indications, revenue could increase, offsetting price erosion.
Key Factors Influencing Market and Price
- Insurance & Access Policies: Reimbursement policies and patient assistance programs will impact net prices.
- Competitive Dynamics: The entry of new agents or biosimilars could drive prices downward.
- Clinical Guidelines: Adoption by leading oncology centers influences prescription volume.
- Regulatory Approvals: Expansion of indications can increase market size.
Conclusion
NDC 70000-0132 (Zepzelca) targets a niche but sizable segment of relapsed SCLC. Initial wholesale prices anchor revenue projections, which are expected to grow modestly with increased adoption. Long-term pricing will be influenced by competitive pressures, reimbursement policies, and clinical guideline updates.
Key Takeaways
- The current U.S. market for Zepzelca is roughly ( \$13- \$20 ) million in year one, scaling to ( \$50- \$100 ) million with greater adoption.
- Price points are anchored around ( \$6,500 ) per cycle, with potential declines as generics enter or biosimilar options emerge.
- Market growth relies heavily on second-line treatment rates, clinical acceptance, and regulatory expansions.
FAQs
Q1: How does Zepzelca differ from traditional irinotecan?
A: Zepzelca uses a liposomal formulation designed to improve delivery and reduce toxicity compared to conventional irinotecan.
Q2: What is the expected timeline for market penetration?
A: Initial uptake is expected within 1-2 years post-approval, with steady growth over 3–5 years.
Q3: Will price reductions occur due to biosimilars?
A: Possible within 5 years if biosimilars enter the market, which could decrease prices by 10-15%.
Q4: How does off-label use impact revenue?
A: Limited, as Zepzelca’s indications are specific; off-label use is unlikely without official approval for broader indications.
Q5: What are the primary barriers to market growth?
A: Competition from generics, reimbursement hurdles, and clinician adoption rates.
References
[1] Centers for Disease Control and Prevention (CDC). Lung Cancer Statistics. 2022.
[2] U.S. Food and Drug Administration (FDA). Zepzelca approval announcement. August 2020.
[3] IQVIA National Prescription Audit. 2022.
[4] Takeda Pharmaceuticals. Zepzelca product overview. 2023.
